 Jazz Pharmaceuticals Plc updated its guidance for 2021 to reflect its acquisition of GW Pharmaceuticals Inc., which closed in early May. Jazz now expects revenue of 3.02 billion to 3.18 billion in 2021, compared with its previous guidance as of May 4 of 2.55 billion to 2.70 billion. 